2Zini N, Santi S, Ognibene A, et al. Discrete localization of different DNA topoisomerases in HeLa and K562 cell neclei and Subnuclear fractions[ J]. Exp Cell Res, 1994,210(2) :336-348.
3Kas E, Laemmli UK. In vivo topoisomerase I cleavage of the Drosophila histo and satellite Ⅱ repeats : DNA sequence and structural characteristics[J]. EMBO J, 1992,11 (2) :705-716.
4Withoff S,De Jong S,De Vries EG, et al .Humanal DNA topoisomerase Ⅱ: biochemistry and role in chemotherapy resistance [ J ]. Anticancer Res, 1996,16(4A) : 1867-1880.
6Chen AY, Liu LF. DNA topoisomerase: essential enzymes and lethal targets[ J]1. Annu Rev Pharmacol Toxicol, 1994,34( 1 ) : 191-218.
7Krishnan P, Bastow KF. Novel mechanism of cellular DNA topoisomerase II inhibition by the pyranonaph thoquinone derivations alpha-lapochone and beta- lapochone [ J ]. Cancer C hemother Pharmacol, 2001,47(3) : 187-198.
8Byl JA, Fortune JM, Burden A, et al. DNA topoisomerases as targets for the anticancer drug TAS-103 :primary cellular target and DNA cleavage enhancement [ J ]. Biochemistry, 1999,38 (4) : 15573-15579.
9Sissi C, Bolgan L, Moro S, et al. DNA-binding preference of bisantrenea nalogues:relevance to the sequence specificity of drug-medlated topoisomerase Ⅱ poisoning[ J ]. Mol Pharmacol, 1998,54(6) : 1036-1045.
10Gantchev TG, Hunting DJ. The ortho-quinonoe metabolite of the anticancer drug etoposide(VP16) is a potent inhibitor of the topoisomerase Ⅱ/DNA cleavable complex [ J ]. Mol Pharmacol, 1998,53 ( 3 ) : 422-428.
8Wang JC. DNA topoisomerases[J]. Annu Rev B3iochem, 1996,65:635- 692.
9Malonne H, Atassi G. DNA topoisomerase targeting drugs: mecha-nisms of action and perspectives[J]. Anti Cancer Drugs, 1997, 8(9):811 -822.
10Krishnan P, Bastow KF. Novel mechanism of cellular DNA topoi-somerase Ⅱ inhibition by the pyranonaphthoquinone derivatives alpha-lapachone and beta-lapachone [J]. Cancer Chemother Pharmacol, 2001, 47(3) : 187-198.
3Xiu-Sheng He Qi Su Zhu-Chu Chen Xiu-Tao He Zhi-Feng Long Hui Ling Liang-Run Zhang Oncology Institute,Nanhua University,Hengyang 421001,Hunan Province,ChinaOncology Institute,Center South University,Changsha 410078,Hunan Province,China Department of Gastroenterology,First People’s Hospital of Changde City,Changde 415003,Hunan Province,China.Expression,deleton and mnutation of ρ16 gene in human gastric cancer[J].World Journal of Gastroenterology,2001,7(4):515-521. 被引量：40
4Scheper R J, Broxterman H J, Scheffer GL, et al. Overexpression of a M (r) 110000 vesicular protein in non-p-glycoprotein-mediated multidrug resistance [ J ]. Cancer Res, 1993, 53(7) : 1475-1479.
5Izquierdo MA. Shoemaker RH, Flens M J, et al. Overlapping phenotypes of multidrug resistance among panels human cancer cell lines [J]. Int J Cancer, 1996, 65(2) :230-237.
6Borst P, Evers R, Kool M, et al. A family of drug transporters : the multidrug resistance-associated proteins [ J ]. J Natl Cancer Inst ,2000,92 (6) : 1295-1302.
7Doyle LA, Ross DD. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2) [ J]. Oncogene ,2003,22:7340-7358.
8Rocchi E, Khodjakov A, Volk EL, et al. The product of the ABC half-transporter gene ABCG2 (BCRP/ABCP) is expressed in the plasma membrane [ J ]. Biochem Biophys Comm, 2000,271 ( 1 ) :42-46.
9Kawabaffa S, Oka M, Shiozawa K, et al. Breast cance resistance protein directly confers SN-38 resistance of lung cancer cells [ J]. Biochem Biophy Res Commun, 2001,280 : 1216-1223.
10Russo D, Marie JP, Zhou DC, et al. Coexpression of anionic glutathione s-transferase (GST pi ) and multidrug resistance genes in acute myelied and lymphoid leukemias [ J ]. Lrukemia , 1994,8:881:884.
